You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

ERYTHROMYCIN ETHYLSUCCINATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Erythromycin Ethylsuccinate, and when can generic versions of Erythromycin Ethylsuccinate launch?

Erythromycin Ethylsuccinate is a drug marketed by Amneal Pharms, Ani Pharms, Cadila Pharms Ltd, Endo Operations, Alpharma Us Pharms, Dista, Naska, Parke Davis, Pharmafair, Aurobindo Pharma Usa, Azurity, and Barr. and is included in fourteen NDAs.

The generic ingredient in ERYTHROMYCIN ETHYLSUCCINATE is erythromycin ethylsuccinate; sulfisoxazole acetyl. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin ethylsuccinate; sulfisoxazole acetyl profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ERYTHROMYCIN ETHYLSUCCINATE?
  • What are the global sales for ERYTHROMYCIN ETHYLSUCCINATE?
  • What is Average Wholesale Price for ERYTHROMYCIN ETHYLSUCCINATE?
Summary for ERYTHROMYCIN ETHYLSUCCINATE
US Patents:0
Applicants:12
NDAs:14
Finished Product Suppliers / Packagers: 5
Raw Ingredient (Bulk) Api Vendors: 48
Clinical Trials: 1
Patent Applications: 1,569
What excipients (inactive ingredients) are in ERYTHROMYCIN ETHYLSUCCINATE?ERYTHROMYCIN ETHYLSUCCINATE excipients list
DailyMed Link:ERYTHROMYCIN ETHYLSUCCINATE at DailyMed
Drug patent expirations by year for ERYTHROMYCIN ETHYLSUCCINATE
Recent Clinical Trials for ERYTHROMYCIN ETHYLSUCCINATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of FloridaPhase 2
Metabolic Solutions Inc.Phase 2

See all ERYTHROMYCIN ETHYLSUCCINATE clinical trials

Pharmacology for ERYTHROMYCIN ETHYLSUCCINATE
Medical Subject Heading (MeSH) Categories for ERYTHROMYCIN ETHYLSUCCINATE

US Patents and Regulatory Information for ERYTHROMYCIN ETHYLSUCCINATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amneal Pharms ERYTHROMYCIN ETHYLSUCCINATE erythromycin ethylsuccinate GRANULE;ORAL 211204-001 Nov 1, 2019 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Pharmafair ERYTHROMYCIN ETHYLSUCCINATE erythromycin ethylsuccinate SUSPENSION;ORAL 062558-001 Mar 15, 1985 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Cadila Pharms Ltd ERYTHROMYCIN ETHYLSUCCINATE erythromycin ethylsuccinate GRANULE;ORAL 216212-002 Nov 21, 2022 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ani Pharms ERYTHROMYCIN ETHYLSUCCINATE erythromycin ethylsuccinate GRANULE;ORAL 062055-003 Nov 2, 2018 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.